|
業務類別
|
Biotechnology |
|
業務概覽
|
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases. |
| 公司地址
| 1715 38th Street, Boulder, CO, USA, 80301 |
| 電話號碼
| +1 720 262-7002 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.edgewisetx.com |
| 員工數量
| 146 |
| Mr. John R. Moore |
General Counsel |
-- |
23/04/2026 |
| Dr. Kevin Koch, PhD |
President, Chief Executive Officer and Director |
美元 670.00K |
23/04/2026 |
| Dr. Joanne M. Donovan, M.D.,PhD |
Chief Medical Officer |
美元 530.36K |
23/04/2026 |
| Mr. Michael P. Nofi |
Chief Financial Officer and Principal Accounting Officer |
美元 67.81K |
23/04/2026 |
| Dr. Alan Russell, PhD |
Chief Scientific Officer and Director |
美元 499.58K |
23/04/2026 |
| Dr. Behrad Derakhshan, PhD |
Chief Operating Officer |
美元 520.00K |
23/04/2026 |
|
|
| Ms. Arlene M. Morris |
Independent Director |
23/04/2026 |
| Ms. Laura A. Brege |
Independent Director |
23/04/2026 |
| Dr. Jonathan D. Root, M.D. |
Independent Director |
23/04/2026 |
| Dr. Kevin Koch, PhD |
President, Chief Executive Officer and Director |
23/04/2026 |
| Dr. Jonathan C. Fox, F.A.C.C.,M.D.,PhD |
Independent Director |
23/04/2026 |
| Dr. Peter Thompson, M.D. |
Chairman of the Board |
23/04/2026 |
| Dr. Badreddin Edris, PhD |
Independent Director |
23/04/2026 |
| Dr. Alan Russell, PhD |
Chief Scientific Officer and Director |
23/04/2026 |
| Mr. Christopher Nathan Martin |
Independent Director |
23/04/2026 |
|
|
|
|
